Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2025-04-02 Proxy Solicitation & In…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Notice of annual general meeting in Alligator Bioscience AB
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of Annual General Meeting' for Alligator Bioscience AB. It contains the agenda, proposed resolutions, and instructions for shareholder participation. This type of document is a standard proxy solicitation and information statement sent to shareholders to inform them of the upcoming meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2025-04-02 English
Kallelse till årsstämma i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is a formal 'Kallelse till årsstämma' (Notice of Annual General Meeting) for Alligator Bioscience AB. It contains the agenda, proposals for board elections, remuneration, and voting procedures for the upcoming AGM. While it contains information typically found in proxy materials, it is specifically a notice of meeting and invitation to shareholders. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category as it provides the necessary information for shareholders to vote at the meeting.
2025-04-02 Swedish
Alligator Bioscience determines record date for reverse share split of ordinary shares and reminds of the recalculation of warrants
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing a reverse share split and the subsequent recalculation of warrant terms. This falls under capital structure changes and share consolidation, which is explicitly covered by the 'Share Issue/Capital Change' (SHA) category. While it mentions an extraordinary general meeting, it is not a voting result announcement (DVA) or a proxy statement (PSI), but rather an operational update on the company's capital structure.
2025-04-01 English
Alligator Bioscience fastställer avstämningsdag för sammanläggning av stamaktier och påminner om omräkning av teckningsoptioner
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Alligator Bioscience announcing the record date for a reverse stock split (sammanläggning av stamaktier) and the subsequent recalculation of terms for outstanding warrants (teckningsoptioner). While it discusses capital structure changes, it is primarily a regulatory announcement regarding corporate actions. According to the 'Menu vs Meal' rule, this document is a short announcement (press release) detailing these changes and providing a link to the full PDF, which classifies it as a Regulatory Filing (RNS).
2025-04-01 Swedish
Change in number of shares and votes in Alligator Bioscience AB
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing a change in the total number of shares and votes in Alligator Bioscience AB due to a rights issue and directed issue. This type of disclosure regarding changes in share capital structure is specifically categorized as a share issue or capital change announcement.
2025-03-31 English
Ändring av antalet aktier och röster i Alligator Bioscience AB
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement regarding a change in the total number of shares and votes in Alligator Bioscience AB due to recent share issuances (rights issue and directed issue). This type of regulatory disclosure, specifically concerning changes in share capital and voting rights, falls under the category of share issues and capital changes.
2025-03-31 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.